| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | YM-155 | CTRPv2 | pan-cancer | AAC | 0.17 | 1e-05 |
| mRNA | Rapamycin | CTRPv2 | pan-cancer | AAC | 0.15 | 1e-05 |
| mRNA | IPA-3 | GDSC1000 | pan-cancer | AAC | 0.14 | 1e-05 |
| mRNA | PD-0325901 | CCLE | pan-cancer | AAC | -0.18 | 2e-05 |
| mRNA | LY-2183240 | CTRPv2 | pan-cancer | AAC | 0.13 | 3e-05 |
| mRNA | PD318088 | CTRPv2 | pan-cancer | AAC | -0.15 | 4e-05 |
| mRNA | sirolimus:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.14 | 4e-05 |
| mRNA | MST-312 | CTRPv2 | pan-cancer | AAC | 0.14 | 6e-05 |
| mRNA | AZD6244 | CCLE | pan-cancer | AAC | -0.17 | 8e-05 |
| mRNA | vincristine | CTRPv2 | pan-cancer | AAC | 0.12 | 8e-05 |